stockrow
Friday 6 November 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
28.85
0.30
+1.05%
Follow VRDN
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
84.43 | 27.86 | 28.19 | 37.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.94) | (18.82) | (16.71) | (111.10) | |
P/B ratio |
3.94 | 3.51 | 3.97 | 4.47 | |
Price to Tangible BV |
4.01 | 3.58 | 3.97 | 4.47 | |
EV/Sales |
57.65 | 17.59 | 18.27 | 25.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.44) | (3.75) | (4.27) | (6.59) | |
EV/FCF |
(4.42) | (3.73) | (4.27) | (6.58) | |
Quick Ratio |
13.64 | 16.56 | 14.71 | 12.37 | |
Current Ratio |
14.46 | 16.95 | 15.15 | 12.65 | |
Net Debt/EBITDA |
9.12 | 5.79 | 6.04 | 6.63 | |
Debt/Assets |
0.00% | 22.07% | 6.39% | 5.55% | |
Debt/Equity |
0.00 | 0.37 | 0.08 | 0.07 | |
Asset Turnover |
0.03 | 0.08 | 0.10 | 0.09 | |
Operating CF/Net income |
0.92 | 0.83 | 1.14 | 0.20 | |
Capex/Depreciation |
0.31 | 0.98 | 0.01 | 0.15 | |
Interest Coverage |
— | (15.20) | (33.56) | (36.93) | |
Research and Development Expense of Revenue |
272.18% | 25,203.17% | 55,057.45% | 67,581.06% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 19,357.39% | 27,431.91% | 25,510.61% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
66.92% | 5,980.28% | 9,496.45% | 9,082.58% | |
Graham Net Nets |
0.25 | 0.33 | 0.32 | 0.27 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.37%) | (18.35%) | (16.97%) | (10.57%) | |
Free Cash Flow Yield |
(15.46%) | (16.91%) | (15.20%) | (10.49%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (0.98) | (1.17) | (0.28) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.99) | (1.17) | (0.28) | |
Cash per Share |
0.00 | 9.10 | 7.46 | 10.31 | |
Shareholders Equity per Share |
0.00 | 6.14 | 6.22 | 8.52 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 6.14 | 6.22 | 8.52 | |
Free Cash Flow |
(93.14) | (106.63) | (119.68) | (23.99) | |
Working Capital |
943.08 | 1,017.48 | 732.94 | 823.54 | |
Capital Expenditures |
(0.37) | (1.31) | (0.02) | (0.24) | |
Net Current Asset Value |
565.16 | 646.13 | 631.74 | 716.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 4.60 | 0.16 | 1.82 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 37.55 | — | — | |
Average Payables |
9.68 | 8.59 | 8.60 | 5.41 | |
Average Assets |
802.90 | 839.78 | 725.00 | 820.91 | |
Average Common Equity |
— | 445.18 | 459.77 | 536.43 |
Columns are period end dates · fundamentals updated 4 Nov 2026